ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Effect of Rituximab Dose as Induction Therapy in ABO Incompatible Living Kidney Transplantation A Systemic Review and Network Meta Analysis

S. Hwang1, W. Park2, K. Kim1, S. Lee1, J. Song1

1Inha University, Incheon, Korea, Republic of, 2Keimyung University, Daegu, Korea, Republic of

Meeting: 2020 American Transplant Congress

Abstract number: D-003

Keywords: B cells, Efficacy, Induction therapy, Infection

Session Information

Session Name: Poster Session D: Kidney Immunosuppression: Induction Therapy

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: ABO-incompatible living kidney transplantation (ABOILKT) has steadily become more widespread. However, the optimal immunosuppressive regimen for ABOILKT remains uncertain. We aimed to determine the outcomes according to dose of rituximab induction.

*Methods: Direct and indirect network meta-analyses using Bayesian models and generation of rankings of rituximab dose via mixed treatment comparison. We searched the following databases for all studies published through to May 15, 2019: Cochrane Central Register, OVID MEDLINE, EMBASE, and PubMed. We reviewed all relevant reviews, registered trials, and relevant conference proceedings to compare clinical outcomes and survival according to dose of rituximab as induction in kidney transplantation

*Results: Twenty-four trias with 4,256 subjects, divided into following four groups: 1) placebo, 2) rituximab 200mg, 3) rituximab 200mg-500mg, 4) rituximab 500mg. Glomerular filtration rates, graft loss, antibody mediated rejection, T-cell mediated rejection, fungal infection (Candida), and patient survival rates did not differ among four groups. However, incidence rate of sepsis 0.728 [95% CrI, 0.572 to 0.926] and CMV infection 0.855 [95% CrI, 0.724 to 0.921] were lower result in using 200mg rituximab group.

*Conclusions: The using of 200mg single dose of rituximab induction in ABOILKR has not only same result about rejection, graft survival and patient’s survival but also low incidence of infection after transplantation

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Hwang S, Park W, Kim K, Lee S, Song J. Effect of Rituximab Dose as Induction Therapy in ABO Incompatible Living Kidney Transplantation A Systemic Review and Network Meta Analysis [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/effect-of-rituximab-dose-as-induction-therapy-in-abo-incompatible-living-kidney-transplantation-a-systemic-review-and-network-meta-analysis/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences